Many Migraine patients, especially who find oral medications don't work well for them and / or have problems with nasal sprays and injections have been waiting for FDA approval of NuPathe, Inc.'s sumatriptan patch Zelrix.
NuPathe received a Complete Response Letter (CRL) from the FDA on August 30 regarding the New Drug Application (NDA) for Zelrix. A CRL is issued by the FDA's Center for Drug Evaluation and Research when the review of an NDA is completed and questions remain that preclude...
